A Study to Investigate the Effectiveness and Safety of Bempedoic Acid in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia in Taiwan

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 180 participants.

Also called NCT06925100

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 180 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06925100
Other papers using this trial's data
  • Effectiveness and Safety of Bempedoic Acid in Taiwanese Patients With Hypercholesterolemia: A Pragmatic Phase 4 Study (CLEAR Taiwan Study) Journal of the American Heart Association, 2026-05-19 DOI, PubMed 42134976, PMC13279464 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06925100. Allocation not applicable; no masking; primary purpose treatment. Start 2025-04-01 (actual); primary completion 2025-10-15 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Investigate the Effectiveness and Safety of Bempedoic Acid in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia in Taiwan
Acronym
CLEAR Taiwan
Condition
Primary Hypercholesterolemia or Mixed Hyperlipidemia
Intervention (Drug)
Bempedoic acid 180 mg tablet
Lead sponsor
Daiichi Sankyo (class: industry)

Record details

Record id
cardio:ct-nct06925100
Content hash
ae2ffb0d655bb3c5ccd31b9cdbb705df5a0aee39d4b3542221cd4a3a061ec065